Brief: Alk-Abello Sees 2023 EBIT Margin At 13-15%

Alk-Abello A/S

03/02/2023 12:16

Feb 3 (Reuters) - ALK-Abello A/S  ALKb.CO :
    * EXPECTS TO CONTINUE ITS TRAJECTORY OF GROWTH AND EARNINGS
IMPROVEMENT IN 2023
    * EXPECTS SALES GROWTH ACROSS ALL REGIONS AND IMPROVED
PROFITABILITY IN  2023
    * 2023 FINANCIAL OUTLOOK: ALK EXPECTS SALES GROWTH ACROSS
ALL
REGIONS AND IMPROVED PROFITABILITY
    * 2023 FINANCIAL OUTLOOK: REVENUE IS EXPECTED TO GROW 7-11%
IN
LOCAL CURRENCIES, EQUALLING 8-12% GROWTH WHEN DISREGARDING A
ONE-YEAR TEMPORARY MANDATORY REBATE INCREASE OF 5 PERCENTAGE
POINTS FOR ALL PRESCRIPTION DRUGS IN GERMANY.
    * 2023 EBIT MARGIN IS EXPECTED AT 13-15% VERSUS 10% IN 2022
    * 2023 FINANCIAL OUTLOOK: EARNINGS WILL BENEFIT FROM REVENUE
GROWTH, ECONOMIES OF SCALE AND LOWER RESEARCH AND DEVELOPMENT
COSTS, DESPITE TOUGHER MARKET CONDITIONS, INCLUDING EFFECT OF
COST INFLATION. EBIT MARGIN IS EXPECTED AT 13-15% VERSUS 10% IN
2022
    * IS EXTENDING RECOMMENDATION THAT DIVIDEND PAYMENTS  BE
SUSPENDED
UNTIL ALK’S PROFITABILITY  FURTHER IMPROVES
    * WE EXPECT CONTINUED GROWTH AND FURTHER EARNINGS
IMPROVEMENTS IN
2023, DESPITE INARGUABLY TOUGHER CONDITIONS, INCLUDING A ONE-OFF
REBATE INCREASE IN GERMANY AND ONGOING INFLATION

Source text for Eikon:  ID:nGNE741FMh 
Further company coverage:  ALKb.CO 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))